Ginkgo Bioworks Acquires Assets from Bitome
June 6, 2022
Ginkgo Bioworks acquired certain assets from Bitome, a Boston-based developer of real-time metabolite monitoring technology, to integrate continuous metabolite monitoring into its cell engineering platform. The acquisition is intended to accelerate design-build-test-learn cycles and bioprocess optimization across Ginkgo’s portfolio of cell programs by providing real-time metabolic data and ML-driven insights.
- Buyers
- Ginkgo Bioworks
- Targets
- Bitome
- Sellers
- Bitome
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
Ginkgo Bioworks Acquires Proof Diagnostics
February 28, 2024
Biotechnology
Ginkgo Bioworks has acquired Proof Diagnostics to integrate Proof's OMEGA nuclease libraries and portable diagnostic technologies into Ginkgo’s gene therapy and genetic medicines platform. The deal expands Ginkgo’s gene editing toolkit and diagnostic capabilities to better serve customers developing programmable medicines and rapid detection systems.
-
Ginkgo Bioworks Acquires Patch Biosciences
February 28, 2024
Biotechnology
Ginkgo Bioworks has acquired Patch Biosciences, a startup that built an AI platform for sequence design to advance genetic medicines. The acquisition will integrate Patch's machine‑learning models and validated assays into Ginkgo's platform to expand its gene therapy, cell therapy and RNA therapeutics capabilities for biopharma customers.
-
Parse Biosciences Acquires Biomage
January 16, 2024
Software
Parse Biosciences has acquired data analysis software company Biomage, integrating Biomage's cloud-based single-cell RNA sequencing analysis platform into Parse's product portfolio. The deal will give Parse customers access to faster, intuitive single-cell data analysis (Biomage's Cellenics/Cellscope), pairing Parse's Evercode combinatorial barcoding technology with Biomage's analysis tools to reduce analysis time and expand capabilities.
-
Ginkgo Bioworks to Acquire Zymergen
July 25, 2022
Biotechnology
Ginkgo Bioworks (NYSE: DNA) has entered into a definitive agreement to acquire Zymergen (Nasdaq: ZY) in an all-stock transaction valued at approximately $300 million market capitalization. The deal is expected to close in the first quarter of 2023, pending Zymergen stockholder approval, regulatory approvals, and other customary closing conditions.
-
Ginkgo Bioworks Acquires Project Beacon COVID-19 LLC
January 19, 2022
Healthcare Services
Ginkgo Bioworks has acquired the assets and operations of Project Beacon COVID-19 LLC, a Boston-based social benefit organization that provided accessible COVID-19 testing across Massachusetts. The acquisition brings Project Beacon's partner relationships, digital platform, and personnel into Ginkgo’s Concentric by Ginkgo public health and biosecurity offering to expand COVID-19 monitoring and testing capabilities.
-
Ginkgo Bioworks Acquires Novogy's Microbial Engineering Platform
December 16, 2020
Biotechnology
Ginkgo Bioworks acquired the main assets of Novogy, Inc., absorbing Novogy's strain assets, IP portfolio, codebase and most of its technical team. The acquisition brings Novogy's expertise in lipid-producing oleaginous yeasts (notably Yarrowia lipolytica) into Ginkgo's cell‑programming platform to accelerate development of bio-based oils, chemicals and materials.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.